v3.26.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Total CVS Health Shareholders’ Equity
Common Shares
Treasury Shares
Common Stock and Capital Surplus
Retained Earnings
Accumulated Other Comprehensive Income
Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024     1,778          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024 [1]       (518)        
Balance at beginning of period at Dec. 31, 2024 $ 75,730 $ 75,560 $ 18 $ (36,818) [1] $ 49,661 [2] $ 62,837 $ (120) $ 170
Shareholders' Equity [Roll Forward]                
Net income 1,782 1,779       1,779   3
Other comprehensive income (loss) 179 179         179  
Stock option activity, stock awards and other (in shares)     1          
Stock option activity, stock awards and other 176 176     176 [2]      
ESPP issuances, net of purchase of treasury shares (in shares) [1]       1        
ESPP issuances, net of purchase of treasury shares 83 83   $ 83 [1]        
Common stock dividends (848) (848)       (848)    
Other (decreases) increases in noncontrolling interests 8 0           8
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2025     1,779          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2025 [1]       (517)        
Balance at end of period at Mar. 31, 2025 77,110 76,929 $ 18 $ (36,735) [1] 49,837 [2] 63,768 59 181
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024     1,778          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024 [1]       (518)        
Balance at beginning of period at Dec. 31, 2024 75,730 75,560 $ 18 $ (36,818) [1] 49,661 [2] 62,837 (120) 170
Shareholders' Equity [Roll Forward]                
Net income 2,795              
Other comprehensive income (loss) 392              
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2025     1,785          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2025 [1]       (518)        
Balance at end of period at Jun. 30, 2025 77,551 77,379 $ 18 $ (36,849) [1] 50,020 [2] 63,936 272 172
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025     1,779          
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025 [1]       (517)        
Balance at beginning of period at Mar. 31, 2025 77,110 76,929 $ 18 $ (36,735) [1] 49,837 [2] 63,768 59 181
Shareholders' Equity [Roll Forward]                
Net income 1,013 1,021       1,021   (8)
Other comprehensive income (loss) 213 213         213  
Stock option activity, stock awards and other (in shares)     6          
Stock option activity, stock awards and other 183 183     183 [2]      
Purchases of treasury shares, net of ESPP issuances (in shares) [1]       (1)        
Purchase of treasury shares, net of ESPP issuances (114) (114)   $ (114) [1]        
Common stock dividends (853) (853)       (853)    
Other (decreases) increases in noncontrolling interests (1) 0           (1)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2025     1,785          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2025 [1]       (518)        
Balance at end of period at Jun. 30, 2025 $ 77,551 77,379 $ 18 $ (36,849) [1] 50,020 [2] 63,936 272 172
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025     1,787          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025 (516)     (516) [3]        
Balance at beginning of period at Dec. 31, 2025 $ 75,382 75,214 $ 18 $ (36,790) [3] 50,402 [4] 61,196 406 168
Shareholders' Equity [Roll Forward]                
Net income 2,957 2,943       2,943   14
Other comprehensive income (loss) (205) (205)         (205)  
Stock option activity, stock awards and other (in shares)     1          
Stock option activity, stock awards and other 277 277     277 [4]      
ESPP issuances, net of purchase of treasury shares (in shares) [3]       1        
ESPP issuances, net of purchase of treasury shares 84 84   $ 84 [3]        
Common stock dividends (857) (857)       (857)    
Other (decreases) increases in noncontrolling interests (1) 0           (1)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2026     1,788          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2026 [3]       (515)        
Balance at end of period at Mar. 31, 2026 $ 77,637 77,456 $ 18 $ (36,706) [3] 50,679 [4] 63,282 201 181
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025     1,787          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025 (516)     (516) [3]        
Balance at beginning of period at Dec. 31, 2025 $ 75,382 75,214 $ 18 $ (36,790) [3] 50,402 [4] 61,196 406 168
Shareholders' Equity [Roll Forward]                
Net income 5,952              
Other comprehensive income (loss) $ (218)              
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2026     1,795          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2026 (517)     (517) [3]        
Balance at end of period at Jun. 30, 2026 $ 79,899 79,702 $ 18 $ (36,852) [3] 50,968 [4] 65,398 188 197
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2026     1,788          
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2026 [3]       (515)        
Balance at beginning of period at Mar. 31, 2026 77,637 77,456 $ 18 $ (36,706) [3] 50,679 [4] 63,282 201 181
Shareholders' Equity [Roll Forward]                
Net income 2,995 2,979       2,979   16
Other comprehensive income (loss) (13) (13)         (13)  
Stock option activity, stock awards and other (in shares)     7          
Stock option activity, stock awards and other 289 289     289 [4]      
Purchases of treasury shares, net of ESPP issuances (in shares) [3]       (2)        
Purchase of treasury shares, net of ESPP issuances (146) (146)   $ (146) [3]        
Common stock dividends $ (863) (863)       (863)    
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2026     1,795          
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2026 (517)     (517) [3]        
Balance at end of period at Jun. 30, 2026 $ 79,899 $ 79,702 $ 18 $ (36,852) [3] $ 50,968 [4] $ 65,398 $ 188 $ 197
[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2025, March 31, 2025 and December 31, 2024.
[2] Common stock and capital surplus includes the par value of common stock of $18 million as of June 30, 2025, March 31, 2025 and December 31, 2024.
[3] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of June 30, 2026, March 31, 2026 and December 31, 2025.
[4] Common stock and capital surplus includes the par value of common stock of $18 million as of June 30, 2026, March 31, 2026, and December 31, 2025.